Last updated: March 25, 2026
What is the drug identified by NDC 00002-8215?
NDC 00002-8215 corresponds to Zyprexa (olanzapine) oral tablets. It is an atypical antipsychotic approved for schizophrenia, bipolar I disorder, and related conditions.
What is the current market size for olanzapine-based products?
The global market for atypical antipsychotics exceeded $22 billion in 2022. Olanzapine accounts for roughly 20% of this segment, translating to an approximate $4.4 billion annual market.
Market segments and geographical breakdown:
| Region |
Market Size (2022) |
Share of olanzapine |
Notes |
| North America |
$12 billion |
30% |
Leading market, high prescription rates |
| Europe |
$6 billion |
18% |
Growing demand with expanding mental health awareness |
| Asia-Pacific |
$3 billion |
25% |
Fastest growth, increasing access to mental health meds |
| Rest of World |
$1.2 billion |
10% |
Lower but rising adoption |
Key drivers:
- Growing prevalence of schizophrenia (~1% globally)
- Rising Bipolar disorder diagnoses
- Off-label uses for mood stabilization
- Patent expiration leading to generic competition
What are the competitive dynamics affecting the price?
Patent expiration and generics:
Olanzapine's primary patent expired in 2010. Generic versions have since dominated the market, causing significant price erosion. Current branded prices are approximately 50-70% lower compared to pre-generic levels.
Market share dynamics:
- Generics control over 90% of prescriptions
- Brand Zyprexa retains niche uses and specific formulations
Pricing trends:
| Year |
Average Wholesale Price (AWP) per 10mg tablet |
Price change compared to previous year |
| 2018 |
$3.25 |
-3% |
| 2019 |
$2.85 |
-12% |
| 2020 |
$2.50 |
-12% |
| 2021 |
$2.10 |
-16% |
| 2022 |
$1.85 |
-12% |
Price drivers:
- Increased competition from generics
- Insurance and formulary restrictions
- Shift toward newer atypicals with improved side-effect profiles (e.g., aripiprazole)
What are the future price projections?
Short-term outlook (2023-2025):
Given the extensive generic market penetration and modest branded sales, prices are expected to stabilize with minor fluctuations. Projected wholesale price per 10mg tablet may range between $1.75 and $2.00.
Long-term outlook (2026-2030):
Limited potential for price increases in the absence of new formulations or indications. Key factors influencing future prices:
- Introduction of biosimilars or fixed-dose combinations
- Changes in patent law or regulatory incentives
- Development of next-generation agents with superior efficacy or safety profiles
Projection models suggest a gradual decline, with prices converging toward $1.50-$1.75 per tablet in 2030.
Contraindications:
- Price stability or slight decline anticipated due to generics
- Potential for price increases if a new formulation receives approval or if patent litigation extends exclusivity
What are the regulatory and policy influences?
- FDA approvals: No recent approvals for new olanzapine formulations or indications.
- Reimbursement policies: Payers favor generics, further reducing prices.
- Patent landscape: No active patents beyond the original; incremental patent protections unlikely.
What are the implications for market players?
- Generics dominate the landscape with aggressive pricing.
- Branded companies must innovate or reposition to maintain margins.
- Investors should anticipate minimal branded sales growth; focus on generic manufacturing, biosimilars, or adjunct therapies.
Key Takeaways
- NDC 00002-8215 (Zyprexa) primarily competes with generics, driving prices downward.
- Market size estimated around $4.4 billion globally, with North America leading.
- Prices have declined substantially after patent expiry, stabilizing around $1.75-$2.00 per 10mg tablet.
- Future price decreases are limited; innovation or regulatory changes are required for significant shifts.
- The dominant driver remains generic competition; branded sales are under pressure.
FAQs
1. Will generics continue to drive prices down?
Yes. The generic market controls over 90% of prescriptions, maintaining downward pressure on prices.
2. Are there upcoming regulatory changes that could affect prices?
No significant approvals or patent extensions are anticipated for olanzapine post-2023.
3. Can new formulations or indications revive pricing?
Potentially. Approval of novel formulations or new therapeutic uses could enable price increases.
4. How does biosimilar competition influence olanzapine’s market?
While biosimilars are less relevant for small molecules like olanzapine, related products or fixed-dose combinations could impact the market.
5. What is the outlook for branded sales?
Branded sales are projected to decline further, with minimal recovery unless new patents or formulations emerge.
References
- MarketWatch. (2023). Global antipsychotics market size.
- IQVIA. (2022). U.S. Prescription Drug Market Data.
- FDA. (2022). Olanzapine drug approval history.
- EvaluatePharma. (2022). Top-selling psychiatric drugs.
- U.S. Patent and Trademark Office. (2023). Patent status of olanzapine compounds.
[1] IQVIA. (2022). IQVIA Institute for Human Data Science.
[2] EvaluatePharma. (2022). Pharmaceutical Market Intelligence.
